Full Text
Economic Evaluation of Dasatinib Compared To Nilotinib as Second Line Treatment of Chronic Myeloid Leukemia in Greece

Abstract

Authors

G Gourzoulidis G Vassilopoulos F Gialama G Kourlaba F Diamantogiannis N Maniadakis

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×